CA Patent

CA3155181A1 — Transdermal delivery of cannabidiol

Assigned to Pike Therapeutics Inc · Expires 2021-04-22 · 5y expired

What this patent protects

Provided is a transdermal drug delivery system comprising cannabidiol, or its salt alone or in combinations thereof. Transdermal delivery can provide a drug plasma concentration at predetermined rate for a predetermined period of time with a simplified therapeutic regimen by decr…

USPTO Abstract

Provided is a transdermal drug delivery system comprising cannabidiol, or its salt alone or in combinations thereof. Transdermal delivery can provide a drug plasma concentration at predetermined rate for a predetermined period of time with a simplified therapeutic regimen by decreasing dosing frequency for the treatment and/or prevention of pain and/or inflammation.

Drugs covered by this patent

Patent Metadata

Patent number
CA3155181A1
Jurisdiction
CA
Classification
—
Expires
2021-04-22
Drug substance claim
No
Drug product claim
No
Assignee
Pike Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.